Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Acta cir. bras ; 30(4): 270-276, 04/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-744283

RESUMO

PURPOSE: To evaluate the effect of parecoxib (an NSAID) on renal function by measuring plasma NGAL (serum neutrophil gelatinase-associated lipocalin) levels in an induced-ischemia rat model. METHODS: Forty male Wistar rats were randomly assigned to one of four groups: Ischemia (I), Ischemia/parecoxib (IP), No-ischemia (NI), and No-ischemia/parecoxib (NIP). Body weight, mean arterial pressure, heart rate, body temperature, NGAL levels, and renal histology were compared across groups. RESULTS: The Ischemia (I) group, which did not receive parecoxib, showed the highest NGAL levels (p=0.001), while the IP group, which received the medication, had NGAL levels similar to those of the non-ischemic (NI and NIP) groups. CONCLUSION: Parecoxib resulted in renal protection in this experimental model. .


Assuntos
Animais , Masculino , Injúria Renal Aguda/prevenção & controle , /uso terapêutico , Modelos Animais de Doenças , Isoxazóis/uso terapêutico , Rim/irrigação sanguínea , Traumatismo por Reperfusão/prevenção & controle , Proteínas de Fase Aguda , Injúria Renal Aguda/patologia , Biomarcadores/sangue , Pressão Sanguínea/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Rim/patologia , Lipocalinas/sangue , Estudos Prospectivos , Proteínas Proto-Oncogênicas/sangue , Distribuição Aleatória , Ratos Wistar , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
3.
The Korean Journal of Internal Medicine ; : 345-353, 2015.
Artigo em Inglês | WPRIM | ID: wpr-63000

RESUMO

BACKGROUND/AIMS: Neutrophil gelatinase-associated lipocalin (NGAL) is a well-known biomarker of acute kidney injury. We evaluated the value of plasma NGAL (pNGAL) as an independent predictor of prognosis in immunoglobulin A nephropathy (IgAN). METHODS: In total, 91 patients with biopsy-proven IgAN at a single center were evaluated. pNGAL was measured using a commercial enzyme-linked immunosorbent assay kit (R&D Systems). Adverse renal outcome was defined as chronic kidney disease (CKD) stage 3 or above at the last follow-up. Pearson correlation coefficient and Cox regression were used for analyses. RESULTS: The mean age of all patients (male:female, 48:43) was 35 years (range, 18 to 77). pNGAL ranged between 21.68 and 446.40 ng/mL (median, 123.97) and showed a correlation with age (r = 0.332, p = 0.001), creatinine (r = 0.336, p = 0.001), estimated glomerular filtration rate (r = -0.397, p 1 g/day (HR, 5.184; 95% CI, 1.124 to 23.921; p = 0.035), and pNGAL (HR, 1.012; 95% CI, 1.003 to 1.022; p = 0.013) were independent predictors associated with adverse renal outcome. CONCLUSIONS: pNGAL showed strong correlations with other clinical prognostic factors and was also an independent predictor of adverse renal outcome. We suggest pNGAL as a potential predictor for prognosis in IgAN, while further studies are needed to confirm the clinical value.


Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Proteínas de Fase Aguda , Biomarcadores/sangue , Biópsia , Distribuição de Qui-Quadrado , Creatinina/sangue , Progressão da Doença , Ensaio de Imunoadsorção Enzimática , Taxa de Filtração Glomerular , Glomerulonefrite por IGA/sangue , Rim/metabolismo , Modelos Lineares , Lipocalinas/sangue , Análise Multivariada , Valor Preditivo dos Testes , Prognóstico , Modelos de Riscos Proporcionais , Proteínas Proto-Oncogênicas/sangue , Insuficiência Renal Crônica/sangue , República da Coreia , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo
4.
The Korean Journal of Internal Medicine ; : 354-361, 2015.
Artigo em Inglês | WPRIM | ID: wpr-62999

RESUMO

BACKGROUND/AIMS: Tubulointerstitial injury plays an important role in the progression of immunoglobulin A nephropathy (IgAN), and neutrophil gelatinase-associated lipocalin (NGAL) is among the most sensitive tubular biomarkers. We investigated whether serum or urine NGAL predicts prognosis in patients with IgAN. METHODS: The present study enrolled patients with biopsy-proven IgAN from January 2005 to December 2010, whose serum and urine samples at the time of kidney biopsy were preserved by freezing. We retrospectively reviewed patient clinical data and followed patients until October 2012. Serum and urine NGAL levels were measured using an enzyme-linked immunosorbent assay kit. Renal progression was defined as an estimated glomerular filtration rate decline by > 50% or progression to end-stage renal disease. RESULTS: There were 121 patients enrolled in this study. During the median follow-up period of 41.49 months, renal progression was found in nine patients (7.4%). Serum or urine NGAL alone could not predict renal progression; however, when serum and urine NGAL levels were combined, belonging to the high NGAL group independently predicted renal progression (hazard ratio [HR], 5.56; 95% confidence interval [CI], 1.42 to 21.73; p = 0.014), along with tubular damage graded according to the Oxford classification as T2 (HR, 8.79; 95% CI, 2.01 to 38.51; p = 0.004). In addition, a Kaplan-Meier curve of renal survival showed significantly higher renal progression in patients in the high NGAL group (log rank, p = 0.004). CONCLUSIONS: In patients with IgAN, high serum and urine NGAL levels at the time of kidney biopsy predict renal progression.


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Proteínas de Fase Aguda/urina , Biomarcadores/sangue , Biópsia , Distribuição de Qui-Quadrado , Progressão da Doença , Ensaio de Imunoadsorção Enzimática , Taxa de Filtração Glomerular , Glomerulonefrite por IGA/sangue , Estimativa de Kaplan-Meier , Rim/metabolismo , Lipocalinas/sangue , Análise Multivariada , Valor Preditivo dos Testes , Prognóstico , Modelos de Riscos Proporcionais , Proteínas Proto-Oncogênicas/sangue , Estudos Retrospectivos , Fatores de Risco
5.
Clinics ; 69(10): 655-659, 10/2014. tab
Artigo em Inglês | LILACS | ID: lil-730461

RESUMO

OBJECTIVES: Video laparoscopic bariatric surgery is the preferred surgical technique for treating morbid obesity. However, pneumoperitoneum can pose risks to the kidneys by causing a decrease in renal blood flow. Furthermore, as in other surgical procedures, laparoscopic bariatric surgery triggers an acute inflammatory response. Neutrophil gelatinase-associated lipocalin is an early and accurate biomarker of renal injury, as well as of the inflammatory response. Anesthetic drugs could offer some protection for the kidneys and could attenuate the acute inflammatory response from surgical trauma. The objective of this study was to compare the effects of two types of anesthetics, propofol and sevoflurane, on the serum levels of neutrophil gelatinase-associated lipocalin during the perioperative period in laparoscopic bariatric surgery. METHODS: Sixty-four patients scheduled for laparoscopic bariatric surgery were randomized into two anesthesia groups and were administered either total intravenous anesthesia (propofol) or inhalation anesthesia (sevoflurane). In the perioperative period, blood samples were collected at three time points (before anesthesia, 6 hours after pneumoperitoneum and 24 hours after pneumoperitoneum) and urine output was measured for 24 hours. Acute kidney injuries were evaluated by examining both the clinical and laboratory parameters during the postoperative period. The differences between the groups were compared using non-parametric tests. ReBEC (http://www.ensaiosclinicos.gov.br/rg/recruiting/): RBR-8wt2fy RESULTS: None of the patients developed an acute kidney injury during the study and no significant differences were found between the serum neutrophil gelatinase-associated lipocalin levels of the groups during the perioperative period. CONCLUSION: The choice of anesthetic drug, either propofol or sevoflurane, did not affect the serum levels of neutrophil gelatinase-associated lipocalin during the perioperative ...


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anestésicos Inalatórios/farmacologia , Anestésicos Intravenosos/farmacologia , Cirurgia Bariátrica/métodos , Lipocalinas/sangue , Éteres Metílicos/farmacologia , Propofol/farmacologia , Proteínas Proto-Oncogênicas/sangue , Cirurgia Vídeoassistida/métodos , Proteínas de Fase Aguda , Anestesia Intravenosa , Injúria Renal Aguda/etiologia , Anestesia Geral/efeitos adversos , Anestesia Geral/métodos , Cirurgia Bariátrica/efeitos adversos , Ensaio de Imunoadsorção Enzimática , Laparoscopia/efeitos adversos , Laparoscopia/métodos , Obesidade Mórbida/cirurgia , Período Perioperatório , Fatores de Risco , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do Tratamento , Cirurgia Vídeoassistida/efeitos adversos
6.
Annals of Laboratory Medicine ; : 354-359, 2014.
Artigo em Inglês | WPRIM | ID: wpr-216389

RESUMO

BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker in the detection of kidney injury. Early diagnosis of urinary tract infection (UTI), one of the most common infections in children, is important in order to avert long-term consequences. We assessed whether serum NGAL (sNGAL) or urine NGAL (uNGAL) would be reliable markers of UTI and evaluated the appropriate diagnostic cutoff value for the screening of UTI in children. METHODS: A total of 812 urine specimens and 323 serum samples, collected from pediatric patients, were analyzed. UTI was diagnosed on the basis of culture results and symptoms reported by the patients. NGAL values were measured by using ELISA. RESULTS: NGAL values were more elevated in the UTI cases than in the non-UTI cases, but the difference between the values were not statistically significant (P=0.190 for sNGAL and P=0.064 for uNGAL). The optimal diagnostic cutoff values of sNGAL and uNGAL for UTI screening were 65.25 ng/mL and 5.75 ng/mL, respectively. CONCLUSIONS: We suggest that it is not appropriate to use NGAL as a marker for early diagnosis of UTI in children.


Assuntos
Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Proteínas de Fase Aguda/urina , Área Sob a Curva , Biomarcadores/sangue , Diagnóstico Precoce , Ensaio de Imunoadsorção Enzimática , Lipocalinas/sangue , Programas de Rastreamento/métodos , Proteínas Proto-Oncogênicas/sangue , Curva ROC , Infecções Urinárias/sangue
7.
J. bras. nefrol ; 35(3): 229-236, jul.-set. 2013.
Artigo em Português | LILACS | ID: lil-687825

RESUMO

A creatinina continua a ser o padrão laboratorial para diagnóstico da injúria renal aguda (IRA). Esforços para prevenção da nefrotoxicidade foram prejudicados pelo atraso no diagnóstico da IRA por critérios utilizando somente a creatinina como marcador, havendo, por isso, grande interesse em identificar mais precocemente biomarcadores confiáveis. Além disso, o tratamento precoce da IRA pode ser correlacionado com um melhor prognóstico e a identificação de biomarcadores para um diagnóstico precoce pode melhorar a eficácia de estratégia terapêutica. Portanto, torna-se imperativo encontrar biomarcadores que possam estratificar corretamente o grau de lesão renal e o risco de desenvolver doença renal crônica (DRC). Aqui, nós revisamos as principais características dos emergentes biomarcadores em nefrologia.


Creatinine remains the standard for laboratory diagnosis of AKI. Efforts to prevent nephrotoxicity have been harmed by the delay in the diagnosis of AKI criteria by using only the creatinine as a marker, therefore there is great interest in identifying early reliable biomarkers. Moreover, early treatment of ARF can be correlated with a better prognosis and identification of biomarkers for early diagnosis would improve the efficacy of a therapeutic strategy. Thus, it becomes imperative to find biomarkers that can stratify correctly the extent of renal damage that each patient has suffered and the risk of developing chronic kidney disease (CKD). Here, we review the main features of emerging biomarkers in nephrology.


Assuntos
Humanos , Injúria Renal Aguda/sangue , Injúria Renal Aguda/diagnóstico , Proteínas de Fase Aguda , Biomarcadores/sangue , Creatinina/sangue , Lipocalinas/sangue , Proteínas Proto-Oncogênicas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA